Australia markets closed

AVXL Jan 2023 30.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
At close: 11:10AM EST
Full screen
Previous close0.1000
Open0.1000
Bid0.0500
Ask0.2000
Strike30.00
Expiry date2023-01-20
Day's range0.1000 - 0.1000
Contract rangeN/A
Volume2
Open interest1.86k
  • Zacks

    Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

    Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

  • Motley Fool

    Is Anavex Life Sciences a Smart Stock to Buy Now?

    Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?

  • GlobeNewswire

    Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

    Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ETNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that management will host